Skip to content Skip to footer
Subscribe Now
INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2025

Shots:  Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B  The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata PharmaShots brings…
April 1, 2025

Read more

NEWS

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to…
January 15, 2025

Read more

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)
INSIGHTS+

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:  In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal valueThis report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…
January 15, 2025

Read more

NEWS

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

Shots:The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024 Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…
January 8, 2025

Read more

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)
INSIGHTS+

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

Shots: The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024 Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion  Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…
January 8, 2025

Read more

PharmaShots Magazine - February 2024 Edition
MAGAZINE

PharmaShots Magazine – February 2024 Edition

PharmaShots February Edition magazine explores the elements of dealmaking in the life sciences and healthcare sector. The magazine unfolds an engaging article followed by illustrative infographics and illuminating BioTrends. The magazine sheds light on key regulatory updates and also includes a few amazing facts on collaboration deals, and mergers & acquisitions. PharmaShots welcomed the year…
February 15, 2024

Read more

Load more